On Feb. 11, 2022, Roche announced that Actemraﾮ/RoActemraﾮ (tocilizumab) intravenous (IV) had been granted World Health Organization (WHO) prequalification. Prequalification was a confirmation by WHO that Actemra/RoActemra met the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.